173 related articles for article (PubMed ID: 18089843)
1. The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity.
Tizzano JP; Stribling DS; Perez-Tilve D; Strack A; Frassetto A; Chen RZ; Fong TM; Shearman L; Krieter PA; Tschöp MH; Skolnick P; Basile AS
J Pharmacol Exp Ther; 2008 Mar; 324(3):1111-26. PubMed ID: 18089843
[TBL] [Abstract][Full Text] [Related]
2. The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats.
Prins J; Westphal KG; Korte-Bouws GA; Quinton MS; Schreiber R; Olivier B; Korte SM
Pharmacol Biochem Behav; 2011 Jan; 97(3):444-52. PubMed ID: 20934452
[TBL] [Abstract][Full Text] [Related]
3. Triple monoamine inhibitor tesofensine decreases food intake, body weight, and striatal dopamine D2/D3 receptor availability in diet-induced obese rats.
van de Giessen E; de Bruin K; la Fleur SE; van den Brink W; Booij J
Eur Neuropsychopharmacol; 2012 Apr; 22(4):290-9. PubMed ID: 21889317
[TBL] [Abstract][Full Text] [Related]
4. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.
Skolnick P; Popik P; Janowsky A; Beer B; Lippa AS
Eur J Pharmacol; 2003 Feb; 461(2-3):99-104. PubMed ID: 12586204
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and clinical pharmacology of DOV 216,303, a "triple" reuptake inhibitor.
Skolnick P; Krieter P; Tizzano J; Basile A; Popik P; Czobor P; Lippa A
CNS Drug Rev; 2006; 12(2):123-34. PubMed ID: 16958986
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of the "triple" monoamine neurotransmitter uptake inhibitor, DOV 102,677.
Popik P; Krawczyk M; Golembiowska K; Nowak G; Janowsky A; Skolnick P; Lippa A; Basile AS
Cell Mol Neurobiol; 2006; 26(4-6):857-73. PubMed ID: 16636898
[TBL] [Abstract][Full Text] [Related]
8. Effect of DOV 102,677 on the volitional consumption of ethanol by Myers' high ethanol-preferring rat.
McMillen BA; Shank JE; Jordan KB; Williams HL; Basile AS
Alcohol Clin Exp Res; 2007 Nov; 31(11):1866-71. PubMed ID: 17908267
[TBL] [Abstract][Full Text] [Related]
9. The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.
Prins J; Denys DA; Westphal KG; Korte-Bouws GA; Quinton MS; Schreiber R; Groenink L; Olivier B; Korte SM
Eur J Pharmacol; 2010 May; 633(1-3):55-61. PubMed ID: 20153745
[TBL] [Abstract][Full Text] [Related]
10. Tesofensine, a monoamine reuptake inhibitor for the treatment of obesity.
Bello NT; Zahner MR
Curr Opin Investig Drugs; 2009 Oct; 10(10):1105-16. PubMed ID: 19777399
[TBL] [Abstract][Full Text] [Related]
11. The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects.
Breuer ME; Chan JS; Oosting RS; Groenink L; Korte SM; Campbell U; Schreiber R; Hanania T; Snoeren EM; Waldinger M; Olivier B
Eur Neuropsychopharmacol; 2008 Dec; 18(12):908-16. PubMed ID: 18789657
[TBL] [Abstract][Full Text] [Related]
12. NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile.
Mastinu A; Pira M; Pani L; Pinna GA; Lazzari P
Behav Brain Res; 2012 Oct; 234(2):192-204. PubMed ID: 22771813
[TBL] [Abstract][Full Text] [Related]
13. "Broad spectrum" antidepressants: is more better for the treatment of depression?
Skolnick P; Popik P; Janowsky A; Beer B; Lippa AS
Life Sci; 2003 Nov; 73(25):3175-9. PubMed ID: 14561522
[TBL] [Abstract][Full Text] [Related]
14. Effects of the triple monoamine uptake inhibitor DOV 102,677 on alcohol-motivated responding and antidepressant activity in alcohol-preferring (P) rats.
Yang AR; Yi HS; Warnock KT; Mamczarz J; June HL; Mallick N; Krieter PA; Tonelli L; Skolnick P; Basile AS; June HL
Alcohol Clin Exp Res; 2012 May; 36(5):863-73. PubMed ID: 22150508
[TBL] [Abstract][Full Text] [Related]
15. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat.
Axel AM; Mikkelsen JD; Hansen HH
Neuropsychopharmacology; 2010 Jun; 35(7):1464-76. PubMed ID: 20200509
[TBL] [Abstract][Full Text] [Related]
16. The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats.
Prins J; Kenny PJ; Doomernik I; Schreiber R; Olivier B; Mechiel Korte S
Eur J Pharmacol; 2012 Oct; 693(1-3):51-6. PubMed ID: 23010469
[TBL] [Abstract][Full Text] [Related]
17. Cetilistat (ATL-962), a novel pancreatic lipase inhibitor, ameliorates body weight gain and improves lipid profiles in rats.
Yamada Y; Kato T; Ogino H; Ashina S; Kato K
Horm Metab Res; 2008 Aug; 40(8):539-43. PubMed ID: 18500680
[TBL] [Abstract][Full Text] [Related]
18. Antiobesity effects of the beta-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats.
Roth JD; Trevaskis JL; Wilson J; Lei C; Athanacio J; Mack C; Kesty NC; Coffey T; Weyer C; Parkes DG
Int J Obes (Lond); 2008 Aug; 32(8):1201-10. PubMed ID: 18560368
[TBL] [Abstract][Full Text] [Related]
19. DOV 216,303, a "triple" reuptake inhibitor: safety, tolerability, and pharmacokinetic profile.
Beer B; Stark J; Krieter P; Czobor P; Beer G; Lippa A; Skolnick P
J Clin Pharmacol; 2004 Dec; 44(12):1360-7. PubMed ID: 15545306
[TBL] [Abstract][Full Text] [Related]
20. Antiobesity activities of indole-3-carbinol in high-fat-diet-induced obese mice.
Chang HP; Wang ML; Chan MH; Chiu YS; Chen YH
Nutrition; 2011 Apr; 27(4):463-70. PubMed ID: 21392705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
